Medical network - on November 9, the ministry, the national development and reform commission, ministry of science and technology, ministry of commerce, state health and family planning commission and the state food and drug supervision administration jointly issued on November 7, the pharmaceutical industry development planning guide, key deployed during the period of "much starker choices-and graver consequences-in" pharmaceutical industry development goals, only has the transition of the big teams in speed up the pharmaceutical industry.

According to the guide, to 2020, the stable growth of our country medicine industry scale, markedly enhance its capability of innovation, improve product quality, supply more perfect security system, speeding up steps of internationalization, pharmaceutical industry overall quality improved.

39 medicine notice, in the pharmaceutical industry's main business income keep high-speed growth, annual growth above 10%, significantly higher proportion of the industrial economy.

Honorary President of the association of business management of Chinese medicine ming-de yu said, "the guide" will no longer continue the previous name of the medicine industry "twelfth five-year" plan, but highlight the "guide" 2 words, fully highlighted its guidance to the development of industry, industry trend is given, and both will help enterprises adjust measures to local conditions.

Integration of policies tend to be big

Pointed out in the "guide", integration of industry restructuring accelerated, increasing concentration, 100 to 2020 years ago of main business income accounted for 10% increase, a large enterprise leading role to further strengthen to the industry development.

Drugs, medical devices quality standards, the quality control standard for effective implementation of each link, ensure to strengthen product quality and safety. Basically completed the basic generic drug oral solid preparation quality and consistency evaluation of curative effect. Through the international advanced level of GMP certification preparation enterprises reached more than 100.

Both in terms of revenue, or generics consistency evaluation, the pharmaceutical industry policy in the future will tend to large enterprises, especially the top drug firms.

Top 39 you understand medicine, China's pharmaceutical industry in 2015, the industry concentration is 46.3%, increased by 7.4% than in 2005, up 0.5% over 2014.

Although the "twelfth five-year" plan for top pharmaceutical industry to achieve the purpose of the 50% still exists a certain gap. But with the acceleration of industry consolidation, especially generics consistency evaluation and two votes to drive industry reshuffle, enterprise merger, acquisition and reorganization efforts, believe that the pharmaceutical industry top concentration "much starker choices-and graver consequences-in" there will be further improved.

Industry transformation innovation become the driving force

Innovation is our country from pharmaceutical powers towards pharmaceutical powers, the only way to realize the industrial transformation and upgrading, but also to break the foreign drug patent medicine on China's high-end market monopoly, to achieve domestic medicine the only means to perfect substitute of the original drug. "Internationalization" of the swimmer, actually also lies in innovation.

The "guide" for and enterprise innovation has definite quantitative indicators: by 2020, the industry enterprises above designated size for transshipment, input intensity reached more than 2%. Innovation quality improved obviously, the new drug registration accounts for the proportion of drug registration, a batch of high quality innovation to realize industrialization, international registration of new drugs to make a breakthrough. Innovative ability in six big government projects, engineering has been ranked first.

Listed in the guide, biological medicine, chemical medicine varieties, high-quality, high-performance medical equipment, new adjuvant in the field of packaging materials and six key pharmaceutical equipment development, the industry is generally believed that biological medicines and proprietary Chinese medicine will become the focus of the industry development in the future.

Analysts pointed out that biological technology gap with the international advanced level in our country is relatively small, can through the efforts to achieve in a short time after, beyond. While many ministries have also been issued documents clearly support the development of proprietary Chinese medicine.